Miguel Islas-Ohlmayer

TL;DR: BV plus bendamustine as first salvage therapy in relapsed/refractory HL is highly active with a manageable toxicity profile and a protocol amendment requiring premedication reduced IRR severity.

TL;DR: This phase 1/2, single-arm, 2-stage, open-label study was designed to evaluate the safety and efficacy of brentuximab vedotin in combination with bendamustine for the treatment of pts with primary refractory disease or in first relapse.

TL;DR: The main toxicity observed with the combination was infusion-related reactions, and the recommended dose of bendamustine in combination with brentuximab vedotin was 90 mg/m 2 .

TL;DR: Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients is determined byThe allele ratio is defined as the sum of the following: A.J.F., Wilson, R.K.

TL;DR: This study used disease re-staging every two cycles to explore the efficacy of using of obinutuzumab, with or without bendamustine prior to initiation of venetoclax, to reduce tumor burden and thus eliminate the need for hospitalizations, as well as reduce the risk for TLS at the initiation of virology therapy.